An innovative product for knee and hip osteoarthritis
Here you will find detailed information on RenehaVis™. Please take some time to browse the sections below.
RenehaVis™ dosage regimen is injection into the affected synovial joint space once a week for up to three injections depending on the severity of the degenerative change to the synovial joint. The duration of effect in patients with grade 1 to 3 medial compartment osteoarthritis of the knee joint has been demonstrated to be up to twelve months.
It should always be administered by a trained medical professional and is given intra-articularly to either the knee joint, into the knee synovial capsule (note: also known as the joint cavity), or the hip, into the hip capsule.
RenehaVis™ is a patented dual chambered syringe containing 2 chambers of different Hyaluronic Acids (HA) that are administered sequentially.
- The first chamber contains a Low Molecular Weight HA in High Concentration.
- The second chamber contains a High Molecular Weight HA in Low Concentration.
RenehaVis™ reduces pain Faster and Better clinically proven in knee study.
A clinical study demonstrated that RenehaVis™ reduced pain during rest and weight bearing in a shorter period than other hyaluronic acids (HA) of either high or low molecular weight.
VAS scores were used for the measurement of pain experienced by patients. The lower the VAS score, the less pain the patient experienced.
Injections were given at week 1, 2 and 3.
Efficacy with RenehaVis™ was seen by the second injection as walking pain improved significantly compared with other study treatments.
RenehaVis™ helps to increase both the lubrication and shock absorbency in the knee and hip joint.
RenehaVis™ helps also to stimulate the endogenous production of natural hyaluronic acid (HA) within the knee and hip joint.
RenehaVis™ effects may last up to at least 12 months after a full treatment.